Pan-cancer onco-signatures reveal a novel mitochondrial subtype of luminal breast cancer with specific regulators.

These findings provide novel genomics evidence for developing personalized breast cancer patient treatments. The onco-signature approach, demonstrated here on breast cancer, is general and can be applied to other cancer types.